Title: | A peptide derived from adaptor protein STAP-2 inhibits tumor progression by downregulating epidermal growth factor receptor signaling |
Authors: | Maemoto, Taiga Browse this author |
Kitai, Yuichi Browse this author →KAKEN DB |
Takahashi, Runa Browse this author |
Shoji, Haruka Browse this author |
Yamada, Shunsuke Browse this author |
Takei, Shiho Browse this author |
Ito, Daiki Browse this author |
Muromoto, Ryuta Browse this author →KAKEN DB |
Kashiwakura, Jun-ichi Browse this author →KAKEN DB |
Handa, Haruka Browse this author |
Hashimoto, Ari Browse this author →KAKEN DB |
Hashimoto, Shigeru Browse this author →KAKEN DB |
Ose, Toyoyuki Browse this author →KAKEN DB |
Oritani, Kenji Browse this author →KAKEN DB |
Matsuda, Tadashi Browse this author →KAKEN DB |
Keywords: | antitumor peptide |
prostate cancer |
STAT3 |
EGFR |
adaptor protein |
Issue Date: | 19-Nov-2022 |
Publisher: | American Society for Biochemistry and Molecular Biology |
Journal Title: | Journal of Biological Chemistry |
Volume: | 299 |
Issue: | 1 |
Start Page: | 102724 |
Publisher DOI: | 10.1016/j.jbc.2022.102724 |
Abstract: | Signal-transducing adaptor family member-2 (STAP-2) is an adaptor protein that regulates various intracellular signals. We previously demonstrated that STAP-2 binds to epidermal growth factor receptor (EGFR) and facilitates its stability and activation of EGFR signaling in prostate cancer cells. Inhibition of this interaction may be a promising direction for cancer treatment. Here, we found that 2D5 peptide, a STAP-2–derived peptide, blocked STAP-2–EGFR interactions and suppressed EGFR-mediated proliferation in several cancer cell lines. 2D5 peptide inhibited tumor growth of human prostate cancer cell line DU145 and human lung cancer cell line A549 in murine xenograft models. Additionally, we determined that EGFR signaling and its stability were decreased by 2D5 peptide treatment during EGF stimulation. In conclusion, our study shows that 2D5 peptide is a novel anticancer peptide that inhibits STAP-2–mediated activation of EGFR signaling and suppresses prostate and lung cancer progression. |
Rights: | https://creativecommons.org/licenses/by/4.0/ |
Type: | article |
URI: | http://hdl.handle.net/2115/87706 |
Appears in Collections: | 薬学研究院 (Faculty of Pharmaceutical Sciences) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|